The $2.7 Million Shot That Replaces a Lifetime of Eating Cornstarch

Patients who received Genglycos saw a 41% average reduction in daily cornstarch intake compared to placebo. That was the primary endpoint, and it was statistically significant. The secondary endpoint showed patients dropped roughly one full cornstarch dose per day versus placebo.

For a disease where every missed dose can send you into a hypoglycemic crisis, cutting out even one daily serving is meaningful. Patients also showed improved fasting tolerance, better blood sugar stability, and fewer episodes of dangerously low glucose. Patient-reported outcomes on the PGIC scale (basically a "how do you feel?" survey) improved too.

Across two clinical studies, 52 patients were treated with up to six years of follow-up data supporting the safety profile.

The Fine Print Matters

This is an accelerated approval, which is the FDA's way of saying: "The early signal looks promising enough to let patients access this now, but we need more proof." The surrogate endpoint here (cornstarch reduction) is a stand-in for the harder question of whether the therapy prevents the serious long-term complications of GSDIa, things like liver tumors, kidney disease, and anemia.

Ultragenyx will need to complete confirmatory studies to keep Genglycos on the market. That's a standard requirement for accelerated approvals, but it's worth noting because this therapy comes with real risks.

The most common side effects were elevated liver enzymes, nausea, headache, constipation, and hyperglycemia. More serious adverse reactions included anaphylaxis, adrenal insufficiency, elevated lactate, and hypoglycemia. The label carries warnings about liver toxicity and tumorigenicity (the potential to contribute to tumor formation). Patients with severe liver fibrosis or cirrhosis are excluded from treatment entirely.

Hypertriglyceridemia (high triglycerides) also showed up more often in treated patients: 29% versus 8% in the placebo group. None of this is disqualifying, but it underscores why careful patient selection and monitoring are critical.

The Price Tag: $2.7 Million

Let's address the elephant in the room. Genglycos carries a U.S. list price of $2.7 million per patient.

That's eye-popping, but it fits the pattern we've seen with one-time gene therapies for rare diseases. The math these companies present usually goes something like this: if you add up the lifetime cost of managing the disease (frequent medical visits, dietary supplements, emergency hospitalizations, lost productivity), a single upfront payment can actually look reasonable by comparison.

Whether insurers and patients agree with that math is a different conversation. Ultragenyx says the therapy should be available through qualified treatment centers within 30 to 60 days.

Why This Approval Is Bigger Than One Disease

GSDIa affects a small number of people. The exact prevalence figures are hard to pin down, but this is firmly in ultra-rare territory. So why should anyone outside that community care?

Because this approval is another proof point for gene therapy in metabolic disease. The FDA's rare metabolic disease landscape has been heating up over the past two years, with approvals for conditions like cerebrotendinous xanthomatosis and TK2 deficiency in 2025, plus a biologic for Hunter syndrome earlier in 2026. Genglycos adds to a growing body of evidence that delivering functional genes to fix broken metabolic pathways actually works in controlled trials.

The program also stacked up an impressive collection of regulatory designations along the way: Fast Track, RMAT (regenerative medicine advanced therapy), orphan drug status from the FDA, plus European orphan drug and EMA PRIME designations. That kind of regulatory enthusiasm signals broad recognition of the unmet need.

The Bottom Line

For decades, families dealing with GSDIa have managed the disease one spoonful of cornstarch at a time, setting alarms through the night, planning every meal around a metabolic clock that never stops ticking. Genglycos won't eliminate that entirely; patients still need nutritional management. But cutting the cornstarch burden significantly, and potentially improving the metabolic stability that diet alone couldn't achieve, is a genuine quality-of-life shift.

The confirmatory trials will tell us whether the long-term benefits hold up. For now, though, a disease that had zero approved treatments finally has one. And for a community that's been surviving on willpower and uncooked cornstarch, that's not nothing.

BMS Just Hired a Robot to Design Its Next Blockbuster Antibody

Bristol Myers Squibb just partnered with a two-year-old AI startup to redesign how it discovers antibodies. Chai Discovery has already landed Eli Lilly, Novartis, and Pfizer as partners, and its AI models are posting hit rates that make traditional screening look ancient.